Vascular endothelial growth factor in pleural fluid

Understanding the biological markers in pleural fluid is crucial for diagnosing thoracic conditions. Prior research has shown that pleural fluid contains various proteins and cytokines that may reflect underlying pathologies. However, the specific role of vascular endothelial growth factor (VEGF) in pleural fluid remains unclear. Established knowledge indicates that VEGF is involved in angiogenesis and fluid regulation. That uncertainty drove the need to investigate how VEGF levels vary across different diagnostic categories. No prior work had resolved whether VEGF could serve as a reliable diagnostic marker in pleural fluid. This gap motivated the current study. Researchers aimed to clarify how VEGF levels correlate with specific thoracic conditions. The diagnostic usefulness of VEGF remains unproven in clinical settings.

This study aimed to explore how vascular endothelial growth factor (VEGF) levels in pleural fluid differ across diagnostic categories. The researchers sought to determine if VEGF could serve as a diagnostic marker in pleural effusions. They focused on comparing VEGF levels in patients with conditions such as malignancy, heart failure, and coronary artery bypass grafting. The motivation came from the need to find a reliable biomarker for thoracic diagnostics. Prior studies had not fully addressed the relationship between VEGF and pleural fluid characteristics. The researchers also wanted to assess how VEGF levels correlate with other fluid markers like lactate dehydrogenase and total protein. This study was designed to provide insights into the biological significance of VEGF in pleural fluid. The findings may suggest new diagnostic approaches for thoracic diseases.

The study measured VEGF levels in pleural fluid from 70 patients undergoing therapeutic thoracentesis. Researchers used an enzyme-linked immunosorbent assay to quantify VEGF concentrations. Patients were grouped by diagnostic category, including malignancy, heart failure, and coronary artery bypass grafting. The study took place at a university-affiliated tertiary care center. VEGF levels were compared across groups to identify differences. Correlations were assessed between VEGF and other fluid markers like lactate dehydrogenase and total protein. Statistical analysis included calculating median values and p-values to determine significance. The researchers also examined how VEGF levels varied in patients with breast cancer versus lung cancer.

The median VEGF level in patients with malignancy was 1,097 pg/mL, significantly higher than in those with heart failure (150 pg/mL) and coronary artery bypass grafting (357 pg/mL). VEGF levels were most strongly correlated with lactate dehydrogenase (r = 0.42, p < 0.001) and total protein levels. Patients with breast cancer had significantly lower VEGF levels than those with lung cancer (p = 0.017). The highest recorded VEGF level was 3,294 pg/mL in a patient with pulmonary embolism. These findings suggest that VEGF levels vary by diagnostic category. However, the overlap between groups limits the usefulness of VEGF as a standalone diagnostic marker. The correlation with lactate dehydrogenase and protein indicates a possible biological relationship. These results may suggest new diagnostic approaches for pleural effusions.

The authors concluded that VEGF levels in pleural fluid differ significantly across diagnostic categories. The highest median levels were observed in patients with malignant pleural effusions. VEGF levels were most closely associated with lactate dehydrogenase and total protein levels. The overlap between groups, however, limits the diagnostic usefulness of VEGF alone. The researchers speculate that VEGF may contribute to pleural fluid accumulation in some cases. These findings may suggest new diagnostic approaches for thoracic conditions. The study does not claim that VEGF is essential for diagnosing pleural effusions. The results may guide future research into the role of VEGF in fluid regulation.